Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients

Journal of Crohn's and Colitis

Volumn 7, Issue 10, 2013, Pages

  Ra, Greta ^a   Thanabalan, Reka ^a   Ratneswaran, Sahana ^a   Nguyen, Geoffrey C ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bleeding; Crohn's disease; Inflammatory bowel disease; Prophylaxis; Ulcerative colitis; Venous thromboembolism

Indexed keywords

FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL FEATURE; CROHN DISEASE; FEMALE; GASTROENTEROLOGY; GENERAL PRACTICE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PHARMACIST; POSTOPERATIVE HEMORRHAGE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SURGERY; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM;

BLEEDING; CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; PROPHYLAXIS; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITAL DEPARTMENTS; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PHARMACY SERVICE, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; POLYSACCHARIDES; RECTUM; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; WARFARIN; YOUNG ADULT;

EID: 84884135963     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.03.002     Document Type: Article

References (25)

1. Solem C.A., Loftus E.V., Tremaine W.J., Sandborn W.J. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004, 99:97-101.
2. Talbot R.W., Heppell J., Dozois R.R., Beart R.W. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986, 61:140-145.
3. Miehsler W., Reinisch W., Valic E., Osterode W., Tillinger W., Feichtenschlager T., et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004, 53:542-548.
4. Bernstein C.N., Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007, 21:507-511.
5. Bernstein C.N., Blanchard J.F., Houston D.S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001, 85:430-434.
6. Murthy S.K., Nguyen G.C. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011, 106:713-718.
7. Nguyen G.C., Sam J.J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008, 103:2272-2280.
8. Grainge M.J., West J., Card T.R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010, 375:657-663.
9. Webberley M.J., Hart M.T., Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993, 34:247-251.
10. Jackson L.M., O'Gorman P.J., O'Connell J., Cronin C.C., Cotter K.P., Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997, 90:183-188.
11. Quera R., Shanahan F. Thromboembolism-an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004, 99:1971-1973.
12. Sam J.J., Bernstein C.N., Razik R., Thanabalan R., Nguyen G.C. Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci 2013 Jan, 58(1):46-52.
13. Dwarakanath A.D., Yu L.G., Brookes C., Pryce D., Rhodes J.M. Sticky' neutro- 6 phils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995, 37:585-588. [7].
14. Gaffney P.R., Doyle C.T., Gaffney A., Hogan J., Hayes D.P., Annis P. Paradoxical response to heparin in 10 patients with 8 ulcerative colitis. Am J Gastroenterol 1995, 90:220-223.
15. Evans R.C., Wong V.S., Morris A.I., Rhodes J.M. Treatment of corticosteroid-resistant ulcerative colitis with heparin-a report 9 of 16 cases. Aliment Pharmacol Ther 1997, 11:1037-1040.
16. Folwaczny C., Wiebecke B., Loeschke K. Unfractionated heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999, 94:1551-1555. [10].
17. Folwaczny C., Fricke H., Endres S., Hart-mann G., Jochum M., Loeschke K. Anti-inflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: a pilot study. Am J Gastroenterol 1997, 92:911-912.
18. Shen J., Ran Z.H., Tong J.L., Xiao S.D. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007, 26:653-663.
19. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
20. Tinsley A., Naymagon S., Trindade A.J., Sachar D.B., Sands B.E., Ullman T.A. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol 2013 Jan, 47(1):e1-e6.
21. Razik R., Bernstein C.N., Sam J., Thanabalan R., Nguyen G.C. Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients. Can J Gastroenterol 2012, 26(11):795-798.
22. American Gastroenterological Association Adult inflammatory bowel disease physician performance measures set [Retrieved August 9, 2012]. http://www.gastro.org/practice/quality-initiatives/IBD_Measures.pdf.
23. Kahn S.R., Lim W., Dunn A.S., Cushman M., Dentali F., Akl E.A., et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141:e195S-e226S.
24. Wallaert J.B., De Martino R.R., Marsicovetere P.S., Goodney P.P., Finlayson S.R., Murray J.J., et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSOIP. Dis Colon Rectum 2012, 55:1138-1144.
25. Bergmann J.F., Cohen A.T., Tapson V.F., Goldhaber S.Z., Kakkar A.K., Deslandes B., et al. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE global survey. Thromb Haemost 2010, 103:736-748.